Zydus Lifesciences Launches Denosumab 120 mg SC for Cancer Patients' Bone Health Protection

Zydus Lifesciences Ltd., an innovation-led healthcare company, has launched a Denosumab biosimilar called 'Zyrifa'. This therapy molecule reduces and delays Skeletal Related Events ('SREs') across solid tumors and multiple myeloma. Priced at Rs 12,495, it aims to provide access and treat patients with bone metastases due to various cancers. The launch is intended to bring affordability and mobility to cancer patients needing critical care, thereby supporting them in their fight against cancer. The company has been launching a wide range of biosimilars to treat various cancers and partnering with diagnostic companies.